(Reuters) – Deficient practices at a lab operated by blood-testing startup Theranos pose “immediate jeopardy to patient health and safety,” the U.S. government’s Centers for Medicare & Medicaid Services said in a letter to the company released on Wednesday. Theranos, founded and led by Elizabeth Holmes, has been in the spotlight after reports in the Wall Street Journal suggested that the company’s blood-testing devices were flawed and had problems with accuracy. The CMS, in a letter to the company dated Jan. 25, told Theranos it had 10 days to provide evidence that it had corrected the issues causing concern.
See more here:
Theranos lab poses ‘jeopardy to patient health’: regulator
